BioSpace News Archive

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2020 .

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2020 and provided an update on key highlights for 2021.

Exo Therapeutics , Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, today announced the appointment of Nagesh Mahanthappa, PhD, to the company’s Board of Directors (BOD) and Charles W. Roberts, MD, PhD, to the company’s Scientific Advisory Board (SAB).

Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Friday, April 23, 2021 at 10:30 a.m. ET to discuss data from the POETYK PSO-1 and POETYK PSO-2 Phase 3 trials of deucravacitinib in patients with moderate-to-severe psoriasis, which will be presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX).

- First milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer’s Research UK Oxford Drug Discovery Institute - Significant advances made in the application of Bicycle technology against emerging antimicrobial and antiviral targets - Additional Bicycles identified through multiple development partnerships

Fourth Quarter Revenues of $3.59 million and Full Year 2020 Revenues of $10.13 million PolarityTE to host conference call and webcast today, March 30, 2021 at 8:00 a.m. ET

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 portion of a study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in patients with newly diagnosed, non-severe lymphopenic high grade glioma (HGG), following standard radiation therapy and temozolomide.

Cybin Inc. ( NEO:CYBN ) ( OTCQB:CLXPF ) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as Chief Operating Officer

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody

Proceeds will support development of novel myeloid checkpoint inhibitors including its clinical program IO-202, a first-in-class LILRB4 antagonist antibody in blood cancers and solid tumors, and its preclinical programs IO-108 and IO-106, targeting LILRB2 and LAIR1 respectively